BMRNBioMarin Pharmaceutical Inc.
What is the market doing?
No clear lean: rangebound and insiders net selling (often routine).
Rangebound, no clear trend. Oversold (RSI 8). Price is −6% vs its 200-day average.
Insiders were net sellers over the 90 days ending Oct 8, 2026; selling is often routine (taxes, diversification).
Moderately shorted, settled Sep 15, 2026, about a week of normal trading to cover. Up 2.0% since the previous count, down from 6.3% of shares outstanding three months ago.
Against the whole market›
Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.
Where this answer is blind. Insider selling is often routine (taxes, diversification); only cluster buying is a strong tell.
How BMRN is trading
BioMarin Pharmaceutical Inc. is +0.81% over the past year while the S&P 500 is +18%: 17 points behind the market.
1-year return · S&P 500 +18%
- vs 200-day average
- −6.0%
vs 200-day average · below trend, but not far
- RSI (14)
- 8
RSI (14) · oversold, sold harder than it has been bought
- Below its 52-week high
- 22%
Below its 52-week high
Details›
- Last close2026-10-09
- $54.80
- 1 monthS&P 500 +2.7%
- −16%
- 1 yearS&P 500 +18%
- +0.81%
- 5 yearsS&P 500 +88%
- −28%
- vs 50-day average$63.43
- −14%
- 52-week high
- $70.23
- 52-week low
- $49.67
- Annualised volatility
- 33%
- Insider buying, net, 6 monthsForms 3/4/5 to 2026-10-09
- −$1.3M
| Year | Return |
|---|---|
| 2026 (year to date) | −7.8% |
| 2025 | −9.6% |
| 2024 | −32% |
| 2023 | −6.8% |
| 2022 | +17% |
| 2021 | +0.75% |
| 2020 | +3.7% |
| 2019 | −0.70% |
| 2018 | −4.5% |
| 2017 | +7.6% |
| Month | Years | Positive | Average |
|---|---|---|---|
| Jan | 10 | 5 of 10 | +1.0% |
| Feb | 10 | 4 of 10 | −1.2% |
| Mar | 10 | 1 of 10 | −3.2% |
| Apr | 10 | 5 of 10 | +0.28% |
| May | 10 | 3 of 10 | −1.6% |
| Jun | 10 | 8 of 10 | +5.0% |
| Jul | 11 | 7 of 11 | +3.1% |
| Aug | 11 | 7 of 11 | −1.1% |
| Sep | 11 | 1 of 11 | −6.2% |
| Oct | 11 | 3 of 11 | −3.9% |
| Nov | 10 | 10 of 10 | +7.3% |
| Dec | 10 | 7 of 10 | +2.2% |
End-of-day closes from IEX; the S&P 500 comparison uses SPY over the same window. Prices are a reference point, not a basis for trading decisions.